期刊文献+

二黄散清除hrHPV的机制 被引量:7

Mechanism of Huang San Ⅱ on hrHPV
原文传递
导出
摘要 目的:探讨含砷复方中药"二黄散"对人乳头状瘤病毒(hrHPV)的作用机制及其治疗宫颈hrHPV阳性者的效果。方法:将二黄散作用于宫颈hrHPV阳性者的宫颈表面。治疗前和治疗后6月分别采用杂交捕获二代法(HC-Ⅱ)检测宫颈局部HPV转阴率,酶联免疫吸附试验ELISA检测血清干扰素γ(IFN-γ)、肿瘤坏死因子α(TNF-α)、白介素4(IL-4)、IL-10水平。结果:治疗后HPV转阴率明显上升、IL-4及IL-10水平均下降,IFN-γ和TNF-α水平上升,治疗前后结果比较均具有显著性差异,且HPV的变化与上述因子水平改变相关。结论:二黄散可能通过调节Th1/Th2的免疫平衡清除hrHPV病毒,可以作为临床治疗hrHPV阳性患者的有效手段。 OBJECTIVE To evaluate the mechanism of the compound Chinese medicine including arsenic "Huang San Ⅱ " on hrHPV and its clinical efficacy on positive hrHPV infectors. METHODS Huang San Ⅱ was used to the patients with cervical positive hrHPV infection. HC-Ⅱ technique was employed to detect the rate of negative conversion before treatment and 6 months later after treatment. We also estimated the varying serum levels of IFN-γ, TNF-α, IL-4, IL-10 by EI,ISA. RESULTS In our study, as the rate of negative conversion ascending , IL-4 and IL-10 levels were all significantly decreased after treatment, while IFN-γand TNF-α values increased spurtly. These variations above all had notable significancy. Further analysis showed there had some correlation between HPV and these factors. CONCLUSION Huang San Ⅱ may regulate Th1/Th2 im mune balance to cleanup HPV. It is of benefit to positive HPV infectors.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2009年第20期1773-1775,共3页 Chinese Journal of Hospital Pharmacy
关键词 含砷复方中药 二黄散 hrHPV 感染者 the compound Chinese medicine including arsenic: Huang San Ⅱ hrHPV infector
  • 相关文献

参考文献9

  • 1Au WY, Kumana CR, Lam CW, et al. Solid tumors subse quent to arsenic trioxide treatment for acute promyelocytic leukemia[J]. Leuk Res,2007,31 ( 1 ) : 105- 108.
  • 2Lin CC, Hsu C, Hsu CH,et al. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial [J]. Invest New Drugs, 2007,25 ( 1 ): 77-84.
  • 3Franco EL,Trottier H. A new window into the natural history of human papillomavirus infection: a view from the ALTS (Atypical Squamous Cells of Undetermined Significance/Low Grade Squamous Intraepithelial Lesions Triage Study) trial [J]. J Infect Dis,2007,195( 11 ) : 1560-1562.
  • 4Grce M,Grahovac B,Rukavina T.etal. HPV testing for cervical cancer screening in Croatia [J]. Coll Antropol, 2007.31 Suppl2 : 67-71.
  • 5el-All HS. Refaat A, Dandash K. Prevalence of cervical neoplastic lesions and Human Papilloma Virus infection in Egypt : National Cervical Cancer Screening Project [J]. Infect Agent Cancer,2007,4(2) : 12.
  • 6Bais AG, Beckmann I, I.indemans J, et al. A shift to a peripheral Th2 type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions[J] J Clin Pathol, 2005.58(10) : 1096-1100.
  • 7Ariyasu T, Tanaka T, Fujioka N, et al. Effects of interferonalpha subtypes on the TH1 TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infectionassociated liver disorders[J]. In Vitro Cell Dev Biol Anim. 2005,41 ( 1-2):50- 56.
  • 8Lehtinen M, Dillner J. Preventive human papillomavirus vaccinalion[J]. Sex Transm Infect ,2002,78( 1 ):4-6.
  • 9Wu JZ,Ho PC. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo grinding[J]. Eur J Pharm Sci, 2006,29( 1 ) : 35- 44.

同被引文献168

引证文献7

二级引证文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部